GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again

As CEO of the largest, most successful drugmaker on the planet, Dave Ricks sure spends a lot of time thinking about risk. Eli Lilly’s weight-loss and diabetes drugs have become wildly successful beyond anyone’s imagination. Its latest 12-month revenue (through June 30) surged 50% to $79.7 billion, with Zepbound (for weight loss) and Mounjaro (for diabetes) accounting for 62% of the total. In November 2025, its market cap crossed the $1 trillion mark, making it the first pharma company to do so (it’s currently hovering around $1.1 trillion). Lilly has more weight-loss game-changers coming. A pill called Foundayo gained FDA approval in April. I (Source: Forbes | Region: Global)